On September 2, 2025, PharmaCyte Biotech, Inc. entered into a $3 million agreement to purchase TNF Pharmaceuticals' Series H convertible preferred stock and warrants convertible into 600,000 common shares, with significant voting and dividend rights, and completed the transaction on September 4, 2025.